|Delayed - 09/23 11:36:50 am|
GSK Announces BENLYSTA Now Approves in Canada in Addition to Standard Therapy for Treatment of Active Lupus Nephritis in Adult Patients07/30/2021 | 10:29am
BENLYSTA (belimumab) has been approved in Canada for the treatment of active lupus nephritis (LN) in adult patients.[i] BENLYSTA is available as an intravenous infusion and a subcutaneous injection. BENLYSTA has been available in Canada as an intravenous infusion since 2011 to reduce disease activity in adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE). It was the first SLE-specific treatment approved in over 50 years. Since then, BENLYSTA has also been approved for subcutaneous injection. The recent approval extends the indication in Canada to include both LN and SLE. BENLYSTA, a human monoclonal antibody, is the first and only biologic approved in Canada for systemic lupus erythematosus and lupus nephritis. This approval follows recent approvals in the US and EU for a similar expanded LN indication.
© S&P Capital IQ 2021
All news about GLAXOSMITHKLINE PLC